Cis- and trans-repression of class I major histocompatibility gene expression in Abelson virus-transformed murine leukemia

Richard A. Zeff, Yu Feng Zhao, Revati Tatake, Herbert M. Lachman, Frank Borriello, Stanley G. Nathenson

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Numerous tumor cell lines of leukemic origin are known to modulate cell surface expression of major histocompatibility complex (MHC) class I antigens resulting in alterations in their immune detection and tumorigenicity. We have been studying the mechanisms responsible for attenuation of MHC class I gene expression in an H-2 heterozygous (H-2b × H-2d) Abelson-Murine leukemia virus (A-MuLV)-transformed leukemic cell line (designated R8). Here we report that treatment of the R8 cell line with the protein synthesis inhibitor cycloheximide (CHX) increased H-2Kb steady-state messenger RNA (mRNA) levels several fold. The induced H-2Kb mRNA transcripts were functional, as demonstrated by their ability to be translated into immunoprecipitable H-2Kb alloantigen. H-2Kb null variants derived from the R8 cell line were shown to be the product of both cis- and trans-acting mechanisms, insomuch as the treatment of R8-derived H-2Kb non-expressor lines with CHX re-established expression of H-2Kb mRNA to the same extent as transfection of the variant cell line with the wild-type H-2Kb gene. Such findings indicate that downregulation of MHC class I gene expression is constitutive for the R8 leukemic cell line, a phenomenon that may be related to the immature pre-B-cell phenotype of this A-MuLV transformant.

Original languageEnglish (US)
Pages (from-to)524-532
Number of pages9
JournalBlood
Volume78
Issue number2
StatePublished - Jul 15 1991
Externally publishedYes

Fingerprint

Abelson murine leukemia virus
Histocompatibility
Viruses
Gene expression
Major Histocompatibility Complex
Cells
MHC Class I Genes
Gene Expression
Cell Line
B-Lymphoid Precursor Cells
Cycloheximide
Messenger RNA
Histocompatibility Antigens Class I
Transformed Cell Line
Protein Synthesis Inhibitors
Isoantigens
Tumor Cell Line
Transfection
Down-Regulation
Phenotype

ASJC Scopus subject areas

  • Hematology

Cite this

Zeff, R. A., Zhao, Y. F., Tatake, R., Lachman, H. M., Borriello, F., & Nathenson, S. G. (1991). Cis- and trans-repression of class I major histocompatibility gene expression in Abelson virus-transformed murine leukemia. Blood, 78(2), 524-532.

Cis- and trans-repression of class I major histocompatibility gene expression in Abelson virus-transformed murine leukemia. / Zeff, Richard A.; Zhao, Yu Feng; Tatake, Revati; Lachman, Herbert M.; Borriello, Frank; Nathenson, Stanley G.

In: Blood, Vol. 78, No. 2, 15.07.1991, p. 524-532.

Research output: Contribution to journalArticle

Zeff, RA, Zhao, YF, Tatake, R, Lachman, HM, Borriello, F & Nathenson, SG 1991, 'Cis- and trans-repression of class I major histocompatibility gene expression in Abelson virus-transformed murine leukemia', Blood, vol. 78, no. 2, pp. 524-532.
Zeff, Richard A. ; Zhao, Yu Feng ; Tatake, Revati ; Lachman, Herbert M. ; Borriello, Frank ; Nathenson, Stanley G. / Cis- and trans-repression of class I major histocompatibility gene expression in Abelson virus-transformed murine leukemia. In: Blood. 1991 ; Vol. 78, No. 2. pp. 524-532.
@article{356c6a95296848089b62729d38f137fd,
title = "Cis- and trans-repression of class I major histocompatibility gene expression in Abelson virus-transformed murine leukemia",
abstract = "Numerous tumor cell lines of leukemic origin are known to modulate cell surface expression of major histocompatibility complex (MHC) class I antigens resulting in alterations in their immune detection and tumorigenicity. We have been studying the mechanisms responsible for attenuation of MHC class I gene expression in an H-2 heterozygous (H-2b × H-2d) Abelson-Murine leukemia virus (A-MuLV)-transformed leukemic cell line (designated R8). Here we report that treatment of the R8 cell line with the protein synthesis inhibitor cycloheximide (CHX) increased H-2Kb steady-state messenger RNA (mRNA) levels several fold. The induced H-2Kb mRNA transcripts were functional, as demonstrated by their ability to be translated into immunoprecipitable H-2Kb alloantigen. H-2Kb null variants derived from the R8 cell line were shown to be the product of both cis- and trans-acting mechanisms, insomuch as the treatment of R8-derived H-2Kb non-expressor lines with CHX re-established expression of H-2Kb mRNA to the same extent as transfection of the variant cell line with the wild-type H-2Kb gene. Such findings indicate that downregulation of MHC class I gene expression is constitutive for the R8 leukemic cell line, a phenomenon that may be related to the immature pre-B-cell phenotype of this A-MuLV transformant.",
author = "Zeff, {Richard A.} and Zhao, {Yu Feng} and Revati Tatake and Lachman, {Herbert M.} and Frank Borriello and Nathenson, {Stanley G.}",
year = "1991",
month = "7",
day = "15",
language = "English (US)",
volume = "78",
pages = "524--532",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "2",

}

TY - JOUR

T1 - Cis- and trans-repression of class I major histocompatibility gene expression in Abelson virus-transformed murine leukemia

AU - Zeff, Richard A.

AU - Zhao, Yu Feng

AU - Tatake, Revati

AU - Lachman, Herbert M.

AU - Borriello, Frank

AU - Nathenson, Stanley G.

PY - 1991/7/15

Y1 - 1991/7/15

N2 - Numerous tumor cell lines of leukemic origin are known to modulate cell surface expression of major histocompatibility complex (MHC) class I antigens resulting in alterations in their immune detection and tumorigenicity. We have been studying the mechanisms responsible for attenuation of MHC class I gene expression in an H-2 heterozygous (H-2b × H-2d) Abelson-Murine leukemia virus (A-MuLV)-transformed leukemic cell line (designated R8). Here we report that treatment of the R8 cell line with the protein synthesis inhibitor cycloheximide (CHX) increased H-2Kb steady-state messenger RNA (mRNA) levels several fold. The induced H-2Kb mRNA transcripts were functional, as demonstrated by their ability to be translated into immunoprecipitable H-2Kb alloantigen. H-2Kb null variants derived from the R8 cell line were shown to be the product of both cis- and trans-acting mechanisms, insomuch as the treatment of R8-derived H-2Kb non-expressor lines with CHX re-established expression of H-2Kb mRNA to the same extent as transfection of the variant cell line with the wild-type H-2Kb gene. Such findings indicate that downregulation of MHC class I gene expression is constitutive for the R8 leukemic cell line, a phenomenon that may be related to the immature pre-B-cell phenotype of this A-MuLV transformant.

AB - Numerous tumor cell lines of leukemic origin are known to modulate cell surface expression of major histocompatibility complex (MHC) class I antigens resulting in alterations in their immune detection and tumorigenicity. We have been studying the mechanisms responsible for attenuation of MHC class I gene expression in an H-2 heterozygous (H-2b × H-2d) Abelson-Murine leukemia virus (A-MuLV)-transformed leukemic cell line (designated R8). Here we report that treatment of the R8 cell line with the protein synthesis inhibitor cycloheximide (CHX) increased H-2Kb steady-state messenger RNA (mRNA) levels several fold. The induced H-2Kb mRNA transcripts were functional, as demonstrated by their ability to be translated into immunoprecipitable H-2Kb alloantigen. H-2Kb null variants derived from the R8 cell line were shown to be the product of both cis- and trans-acting mechanisms, insomuch as the treatment of R8-derived H-2Kb non-expressor lines with CHX re-established expression of H-2Kb mRNA to the same extent as transfection of the variant cell line with the wild-type H-2Kb gene. Such findings indicate that downregulation of MHC class I gene expression is constitutive for the R8 leukemic cell line, a phenomenon that may be related to the immature pre-B-cell phenotype of this A-MuLV transformant.

UR - http://www.scopus.com/inward/record.url?scp=0025916968&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025916968&partnerID=8YFLogxK

M3 - Article

VL - 78

SP - 524

EP - 532

JO - Blood

JF - Blood

SN - 0006-4971

IS - 2

ER -